Egros Fabrice 4
4 · Syndax Pharmaceuticals Inc · Filed Nov 19, 2021
Insider Transaction Report
Form 4
Egros Fabrice
Director
Transactions
- Exercise/Conversion
Common Stock
2021-11-18$8.93/sh+14,000$125,020→ 30,000 total - Exercise/Conversion
Stock Options (Right to buy)
2021-11-18−14,000→ 0 totalExercise: $8.93Exp: 2028-05-23→ Common Stock (0 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2021-11-18−30→ 0 totalExercise: $7.88Exp: 2029-06-10→ Common Stock (0 underlying) - Sale
Common Stock
2021-11-18$18.03/sh−14,000$252,452→ 16,000 total - Exercise/Conversion
Common Stock
2021-11-18$7.88/sh+30$236→ 16,030 total - Sale
Common Stock
2021-11-18$18.03/sh−30$541→ 16,000 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
- [F2]The sale prices ranged from $18.03 to $19.03.
- [F3]This option is fully vested.